Your browser doesn't support javascript.
loading
Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models.
Mohr, Corinna J; Schroth, Werner; Mürdter, Thomas E; Gross, Dominic; Maier, Selina; Stegen, Benjamin; Dragoi, Alice; Steudel, Friederike A; Stehling, Severine; Hoppe, Reiner; Madden, Stephen; Ruth, Peter; Huber, Stephan M; Brauch, Hiltrud; Lukowski, Robert.
Afiliación
  • Mohr CJ; Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany.
  • Schroth W; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany.
  • Mürdter TE; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany.
  • Gross D; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany.
  • Maier S; Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany.
  • Stegen B; Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany.
  • Dragoi A; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany.
  • Steudel FA; Department of Radiation Oncology, University of Tuebingen, Tuebingen, Germany.
  • Stehling S; Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany.
  • Hoppe R; Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany.
  • Madden S; Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany.
  • Ruth P; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany.
  • Huber SM; RCSI Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Brauch H; Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tuebingen, Tuebingen, Germany.
  • Lukowski R; Department of Radiation Oncology, University of Tuebingen, Tuebingen, Germany.
Br J Pharmacol ; 179(12): 2906-2924, 2022 06.
Article en En | MEDLINE | ID: mdl-32468618
ABSTRACT
BACKGROUND AND

PURPOSE:

Pore-forming α subunits of the voltage- and Ca2+ -activated K+ channel with large conductance (BKα) promote malignant phenotypes of breast tumour cells. Auxiliary subunits such as the leucine-rich repeat containing 26 (LRRC26) protein, also termed BKγ1, may be required to permit activation of BK currents at a depolarized resting membrane potential that frequently occur in non-excitable tumour cells. EXPERIMENTAL

APPROACH:

Anti-tumour effects of BKα loss were investigated in breast tumour-bearing MMTV-PyMT transgenic BKα knockout (KO) mice, primary MMTV-PyMT cell cultures, and in a syngeneic transplantation model of breast cancer derived from these cells. The therapeutic relevance of BK channels in the context of endocrine treatment was assessed in human breast cancer cell lines expressing either low (MCF-7) or high (MDA-MB-453) levels of BKα and BKγ1, as well as in BKα-negative MDA-MB-157. KEY

RESULTS:

BKα promoted breast cancer onset and overall survival in preclinical models. Conversely, lack of BKα and/or knockdown of BKγ1 attenuated proliferation of murine and human breast cancer cells in vitro. At low concentrations, tamoxifen and its major active metabolites stimulated proliferation of BKα/γ1-positive breast cancer cells, independent of the genomic signalling controlled by the oestrogen receptor. Finally, tamoxifen increased the relative survival time of BKα KO but not of wild-type tumour cell recipient mice. CONCLUSION AND IMPLICATIONS Breast cancer initiation, progression, and tamoxifen sensitivity depend on functional BK channels thereby providing a rationale for the future exploration of the oncogenic actions of BK channels in clinical outcomes with anti-oestrogen therapy. LINKED ARTICLES This article is part of a themed issue on New avenues in cancer prevention and treatment (BJP 75th Anniversary). To view the other articles in this section visit http//onlinelibrary.wiley.com/doi/10.1111/bph.v179.12/issuetoc.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Canales de Potasio de Gran Conductancia Activados por el Calcio Límite: Animals / Female / Humans Idioma: En Revista: Br J Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Canales de Potasio de Gran Conductancia Activados por el Calcio Límite: Animals / Female / Humans Idioma: En Revista: Br J Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Alemania